Wells Fargo & Company Xenetic Biosciences, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.31 - $0.73 $0 - $1	2 Added 1.94%	105 $0
Q4 2022 Feb 13, 2023	BUY	$0.27 - $5.75 $2 - $46	8 Added 8.42%	103 $0
Q3 2022 Nov 14, 2022	BUY	$0.59 - $5.57 $4 - $38	7 Added 7.95%	95 $0
Q2 2022 Aug 12, 2022	BUY	$0.6 - $1.14 $7 - $13	12 Added 15.79%	88 $0
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.08 $34 - $56	27 Added 55.1%	76 $0
Q3 2021 Nov 15, 2021	SELL	$1.73 - $5.3 $12 - $37	-7 Reduced 12.5%	49 $0
Q2 2021 Aug 16, 2021	SELL	$1.57 - $2.45 $1 - $2	-1 Reduced 1.75%	56 $0
Q1 2021 May 13, 2021	BUY	$2.01 - $3.5 $36 - $63	18 Added 46.15%	57 $0
Q3 2020 Nov 05, 2020	BUY	$0.83 - $1.56 $10 - $20	13 Added 50.0%	39 $0
Q1 2020 May 14, 2020	BUY	$0.49 - $1.69 $12 - $43	26 New	26 $0

Ticker XBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,166,600
Market Cap $64.6M
Description
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-base...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.